Global Access to Nutrition Index 2021 Calls for Food Industry to Urgently Address Nutrition Gap in the COVID-19 Era
Access to Nutrition Initiative (ATNI) has launched its 2021 Global Index, assessing the world’s 25 largest global food and beverage manufacturers and their contributions to addressing malnutrition. While some companies have shown significant progress since it’s last iteration in 2018, progress from the top 10 ranking manufacturers has slowed. ATNI is urgently calling on companies to step up efforts to tackle some of the world’s toughest nutrition challenges.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210701005100/en/
Global Access to Nutrition Index 2021 Final Ranking (Graphic: Business Wire)
Malnutrition in any form affects every county in the world, contributing towards millions of deaths and people at risk of diet related diseases. In 2019, 690 million people (8.9% of the global population) were considered undernourished, and with the economic effects of COVID-19 we’re seeing even more people experiencing extreme poverty and the consequences of overweight and diet-related diseases.
FCDO Minister for the European Neighbourhood and the Americas, Wendy Morton said: “We welcome the launch of this year’s Index, particularly as COVID-19 has worsened levels of malnutrition and the availability of food globally. We have a unique opportunity to address this in ways that benefit everyone. We must hold the world’s biggest food and beverage companies to account to help speed up our global recovery from the pandemic.”
Inge Kauer, Executive Director of ATNI, added, “As the 25 largest food and beverage manufacturers, each must take responsibility to deliver healthy product offerings to consumers across the globe and not leave nutrition behind. That’s no small task – but it’s one that requires action urgently if we are to deliver on the Sustainable Development Goals to end world hunger and ensure good health and well-being.”
Highlights and Rankings
All companies were assessed on their commitments, practices, and disclosure – with regards to governance and management, the production and distribution of healthy, affordable, accessible products, and how companies influence consumer choices and behavior.
- The average score remained the same as 2018: 3.3/10.
- Nestlé led the 2021 ranking with a score of 6.7. The company achieved a top-3 rank in all categories and ranked first on ‘Governance’, and ‘Engagement’.
- Unilever came second with 6.3, and FrieslandCampina third with 5.9.
- Arla showed a big improvement from 3.3 in 2018 to 5.1 in 2021, largely because of a new labeling policy, responsible marketing policies, and an improvement in healthiness of its product portfolio.
- Meiji rose four places, partially due to incorporation of a nutrition strategy in its CSR vision and new policies aimed at marketing to children and labeling.
- Only 31% of products met the independent health standard (a health star rating of 3.5 stars or more). This equates to 11,797 of the 38,176 distinct products sold by the 25 companies globally
- Just five companies were found to have half or more of their products meet the healthy threshold of 3.5 stars
- Nine companies improved the average HSR of their products between 2018 and 2021.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Relief Announces Receipt of U.S. FDA Orphan Drug Designation for the use of RLF-100 (aviptadil) in the Treatment of Sarcoidosis3.8.2021 07:03:00 CEST | Press release
RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (“Relief” or the "Company"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that, via its newly acquired subsidiary, AdVita Lifescience GmbH, the Company has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (“FDA”) for RLF-100 (aviptadil), an inhaled formulation in development for the treatment of sarcoidosis. RLF-100 is a synthetic form of vasoactive intestinal peptide. In open label exploratory clinical experience in sarcoidosis patients, RLF-100 has been shown to be well tolerated and safe, and to produce favorable immunoregulatory effects in the lungs that have been associated with symptom relief in a significant proportion of the patients. “Receipt of our third Orphan Drug Designation is another important milestone for the Company, as it underscores the potential strength of our pipeline and the high need for be
Smart Engages P.I. Works for Expanded Network Automation Solution3.8.2021 07:00:00 CEST | Press release
Smart Communications, Inc. (Smart), the wireless unit of the Philippines’ largest, fully integrated telecommunications company PLDT, has partnered with P.I. Works for a comprehensive strategy for its Self-Organizing Network (SON) Solution to automate its multi-vendor, multi-technology networks. A self-organizing network (SON) is an automation technology designed to make the planning, configuration, performance management, coverage and quality optimization and healing of mobile radio access networks efficient, simpler and faster. This automation is expected to significantly improve the performancemanagement and service quality enhancements of the Smart wireless network, which will result in an improved experience for Smart customers across the country. Under its Network Operations Transformation program, Smart started working with P.I. Works in 2018 through another entity, to enable Artificial Intelligence (AI) and Machine Learning (ML) technologies for the automation of various network
Personalis, Inc. Publishes New Data Demonstrating a Novel Composite Biomarker NEOPS™ for Predicting Response to Cancer Immunotherapy in Late-Stage Melanoma Patients2.8.2021 22:05:00 CEST | Press release
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced translational genomics and diagnostics for cancer, today announced the publication of its study "Prediction of immunotherapy response in melanoma through combined modeling of neoantigen burden and immune-related resistance mechanisms,"(1) in Clinical Cancer Research, a journal published by the American Association for Cancer Research. The study details the development of the Personalis Neoantigen Presentation Score (NEOPS™), a novel composite biomarker for predicting response to cancer immunotherapy. Enabled by comprehensive tumor immunogenomic profiling from the Personalis NeXT Platform, NEOPS simultaneously models both neoantigen burden and immune-related resistance mechanisms to better predict immunotherapy response in a cohort of late-stage melanoma patients. In this study, NEOPS was more strongly predictive of therapy response than other standard single analyte and investigational biomarkers tested, including tumor mutational b
The Consortium Welcomes Playtech’s Confirmed Recommendation for Its Binding Agreement to Acquire Finalto and Urges Investors to Vote in Favour at the Playtech Adjourned General Meeting on 18 August 20212.8.2021 19:41:00 CEST | Press release
Finalto S.P.V. Ltd, the consortium led by Barinboim Group and backed by Leumi Partners Limited and Menora Mivtachim Group, together with key members of the Finalto Business' management team (together the "Consortium"), welcomes the announcement by Playtech plc (“Playtech”) confirming its recommendation that shareholders vote in favour of the Consortium’s binding agreement for Finalto Group (“Finalto) (the “Binding Agreement”). Playtech announced today that following its engagement with Gopher Investments (“Gopher”) over the past three weeks, it has not received responses from Gopher to a number of its questions and therefore “Playtech has not yet been able to achieve the necessary clarity on Gopher's ultimate ownership and funding structure, source of funds or ability to obtain the required regulatory clearances”. Shareholders should ask why Gopher continues to hide and should also be suspicious of Gopher’s credibility, particularly given that disclosure is crucial when buying a highly
Lenovo Climbs 65 Places to Record #159 On ‘FORTUNE Global 500’ List2.8.2021 17:09:00 CEST | Press release
After achieving historical 2021 fiscal year results, Lenovo has been ranked #159 on FORTUNE’s annual Global 500 List and in the top 20 (#15) of all Technology sector companies cited in the List. Lenovo jumped 65 spots this year to an all-time high ranking due to its record financial results, which saw the Group surge past the US$60 billion revenue mark, and adding more than US$10 billion from the previous fiscal year as all core businesses grew. The Fortune Global 500 is the annual ranking of the largest 500 corporations in the world as measured by total revenue. Together, companies on The Global 500 generated US$31.7 trillion in revenue and US$1.6 trillion in profits in 2020, employ 69.7 million people worldwide and are represented by 31 countries. Lenovo’s updated ranking reflects the company’s clear strategy, product innovation, operational excellence, and global/local footprint within the past year. These results reinforced the company’s resilience and ability to achieve balanced,
From Panasonic i-PRO Sensing Solutions to “i-PRO”, Renewing Its Company Name From April 20222.8.2021 17:00:00 CEST | Press release
Panasonic i-PRO Sensing Solutions Co., Ltd. will renew its company name to "i-PRO Co., Ltd." on April 1, 2022. Our company was established in October 2019 as a business separation from Panasonic Corporation, and we have incorporated the network camera brand "i-PRO" into our company name. With the new brand "i-PRO", we have been developing and delivering products that incorporate various innovations to our customers, with "Extend human senses through technology, to capture moments of truth so the front-line professionals can act." as our brand purpose for our existence in society. With our global headquarters located in Japan, we will continue our daily efforts to innovate and develop a range of products under the global brand name "i-PRO", which will be launched in markets around the world. In advance of it, i-PRO EMEA B.V. will be headquartered in Amsterdam and start operations as of October 1st, 2021, in the transition of its European Security and Industrial Medical Vision (IMV) busi
Technology Innovation Institute Appoints Eminent Technologist Dr Ray O. Johnson as CEO2.8.2021 15:54:00 CEST | Press release
Technology Innovation Institute (TII), the applied research pillar of the Advanced Technology Research Council (ATRC), the overarching advanced technology body in Abu Dhabi responsible for driving research and development for transformative technology outcomes, today announced the appointment of veteran technologist and entrepreneur Dr Ray O. Johnson as Chief Executive Officer. Dr Johnson will work on shaping the strategic direction of the Institute and lead the execution of its growth strategies to achieve operational excellence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210802005462/en/ Dr Ray O. Johnson, Chief Executive Officer, Technology Innovation Institute (Photo: AETOSWire) Prior to joining TII, Dr Johnson was an Operating Partner at Bessemer Venture Partners, a top-tier American venture capital company that has been part of 130 IPOs in the last 50 years, and before that, he was the Corporate Senior Vice Preside
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom